These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 35022193)

  • 1. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
    Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.
    Wang J; Zhang J; Gao J; Zhao M; Ma Z
    Adv Clin Exp Med; 2024 Jun; 33(6):573-581. PubMed ID: 37676100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
    Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
    Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
    Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
    Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
    Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.
    Feng T; Li Q; Zhu R; Yu C; Xu L; Ying L; Wang C; Xu W; Wang J; Zhu J; Huang M; Xu C; Jin J; Zhang X; Lu T; Yang Y; Zhu C; Chen Q; Su D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
    Qin J; Xue L; Hao A; Guo X; Jiang T; Ni Y; Liu S; Chen Y; Jiang H; Zhang C; Kang M; Lin J; Li H; Li C; Tian H; Li L; Fu J; Zhang Y; Ma J; Wang X; Fu M; Yang H; Yang Z; Han Y; Chen L; Tan L; Dai T; Liao Y; Zhang W; Li B; Chen Q; Guo S; Qi Y; Wei L; Li Z; Tian Z; Kang X; Zhang R; Li Y; Wang Z; Chen X; Hou Z; Zheng R; Zhu W; He J; Li Y
    Nat Med; 2024 Sep; 30(9):2549-2557. PubMed ID: 38956195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
    Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
    EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
    Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
    Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
    Zhou RQ; Luo J; Li LJ; Du M; Wu QC
    BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
    Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X
    J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
    Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
    [No Abstract]   [Full Text] [Related]  

  • 15. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
    Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.
    Wang H; Jiang Z; Wang Q; Wu T; Guo F; Xu Z; Yang W; Yang S; Feng S; Wang X; Chen S; Cheng C; Chen W
    Eur J Cancer; 2023 Jun; 186():196-210. PubMed ID: 37045666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of
    Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
    Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
    Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.